Partners Bio Discovery 4 Fc... Net Worth

The estimated Net Worth of Partners Bio Discovery 4 Fc... is at least $219 Milhão dollars as of 17 January 2020. Partners Fc owns over 300,000 units of Axonics Inc stock worth over $203,266,295 and over the last 6 years Partners sold AXNX stock worth over $15,681,000.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Partners Fc AXNX stock SEC Form 4 insiders trading

Partners has made over 3 trades of the Axonics Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Partners sold 300,000 units of AXNX stock worth $9,459,000 on 17 January 2020.

The largest trade Partners's ever made was buying 866,666 units of Axonics Inc stock on 2 November 2018 worth over $12,999,990. On average, Partners trades about 488,889 units every 147 days since 2018. As of 17 January 2020 Partners still owns at least 2,957,461 units of Axonics Inc stock.

You can see the complete history of Partners Fc stock trades at the bottom of the page.

What's Partners Fc's mailing address?

Partners's mailing address filed with the SEC is 374 RUE SAINT ST HONORE ST.374 RUE SAINT ST HONORE ST., , 75001 PARIS75001 PARIS, , .

Insiders trading at Axonics Inc

Over the last 6 years, insiders at Axonics Inc have traded over $108,010,643 worth of Axonics Inc stock and bought 4,672,163 units worth $70,180,620 . The most active insiders traders include Asset Management, Lp Chen B..., Shahzad Malik, eGeoff Pardo. On average, Axonics Inc executives and independent directors trade stock every 15 days with the average trade being worth of $4,280,711. The most recent stock trade was executed by Raymond W Cohen on 24 July 2024, trading 103,896 units of AXNX stock currently worth $2,383,374.

What does Axonics Inc do?

axonics modulation technologies, inc is a privately-held medical device company developing an innovative neuromodulation platform based on a miniaturized rechargeable fully-implantable ipg licensed from the alfred mann foundation. the axonics sacral neuromodulation system is designed to improve the experience of both clinicians and patients suffering from urinary and fecal dysfunction.

Complete history of Partners Fc stock trades at Axonics Inc

Axonics Inc executives and stock owners

Axonics Inc executives and other stock owners filed with the SEC include:

• Raymond Cohen,
  Chief Executive Officer, Director
• Dan Dearen,
  President, Chief Financial Officer
• Rinda Sama,
  Chief Operating Officer
• Raymond W. Cohen,
  CEO & Director
• Danny L. Dearen,
  Pres & CFO
• Dr. Karen L. Noblett M.D., M.A.S.,
  Chief Medical Officer
• Rinda K. Sama,
  Chief Operating Officer
• Robert McNamara,
  Independent Director
• Juliet Tammenoms Bakker,
  Independent Director
• Alfred J. Ford Jr.,
  Chief Commercial Officer
• Erik Amble,
  Independent Director
• Michael Carrel,
  Independent Chairman of the Board
• Jane Kiernan,
  Independent Director
• Nancy Snyderman,
  Independent Director
• Karen Noblett,
  Chief Medical Officer
• Prabodh Mathur,
  Chief Product Development Officer
• Alfred Ford,
  Chief Commercial Officer
• John Woock,
  Chief Marketing Officer
• Dr. Karen L. Noblett M.A.S., M.D.,
  Chief Medical Officer
• Michael V. Williamson Esq., J.D.,
  Sr. VP, Gen. & IP Counsel
• Michael V. Williamson,
  Sr. VP, Gen. & IP Counsel
• Dr. John Woock Ph.D.,
  Exec. VP, Chief Marketing & Strategy Officer
• Aaron Pettit,
  Gen. Counsel & Chief Compliance Officer
• Neil Bhalodkar,
  VP of Investor Relations
• Guangqiang Jiang Ph.D.,
  Chief Technology Officer
• Esteban Lopez,
  
• John George Petrovich,
  Director
• Shahzad Malik,
  Director
• Life Sciences Llp Advent Li...,
  
• Partners Bio Discovery 4 Fc...,
  
• E. Mann Foundation For Scie...,
  
• Capital Partners Iii, Llcen...,
  
• Innovation V Ltd Neo Med In...,
  
• Healthcare Holding B.V.Gild...,
  
• Asset Management, Lp Chen B...,
  
• Michael V. Williamson,
  SVP, General Counsel
• Guangqiang Jiang,
  Chief Technology Officer
• Zhong Zac & Cloud Holdings ...,
  
• Raphael Wisniewski,
  
• Robert E Mcnamara,
  
• Geoff Pardo,
  
• David M Demski,
  
• Kari Leigh Keese,
  Chief Financial Officer